Sooo, I just watched this.
Some takeaways for me.
Drug affect size has been calculated statistically based on the PAR005 and PAR008 trials, with a 'success' result estimated in Phase III to be 98-99%.
Yes, they calculated the average based on 005 and 008 and still got this result.
I can only imagine what it would be if they discarded the poorer 005 results.
Paul confirmed that active partnership meetings are on hold, pending the FDA tick for phase III
Once again, I heard no bad news.
Not advice, just my thoughts
LiveStream: Paradigm Biopharma (ASX:PAR) pursuing FDA review, page-10
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
-0.005(1.69%) |
Mkt cap ! $112.9M | |||
| Open | High | Low | Value | Volume |
| 29.5¢ | 31.0¢ | 28.5¢ | $431.5K | 1.469M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 21578 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 9000 | 1 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| PAR (ASX) Chart |